anti-HRAS (HRAS) Antikörper

anti-V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog Antikörper (HRAS)
Auf finden Sie aktuell 143 V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Antikörper von 24 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen HRAS Proteine (19) und HRAS Kits (17) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 190 HRAS Produkte verfügbar.
AI929937, C-BAS/HAS, c-H-ras, c-Ha-ras, C-HA-RAS1, c-rasHa, CTLO, H-ras, H-RASIDX, Ha-ras, HAMSV, Harvey-ras, hras, Hras-1, HRAS1, K-ras, Ki-ras, Kras-2, Kras2, N-RAS, p21B, ras, RASH1, zgc:110250

Meistgesuchte Reaktivitäten zu anti-HRAS (HRAS) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Human HRAS Antikörper:

anti-Rat (Rattus) HRAS Antikörper:

anti-Mouse (Murine) HRAS Antikörper:

Alle verfügbaren anti-HRAS Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-HRAS Antikörper

  1. Human Polyclonal HRAS Primary Antibody für EIA, IF - ABIN952792 : Ma, Liu, Wu, Terada: p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. in Oncogene 2010 (PubMed)
    Zeige alle 5 Referenzen für 952792

  2. Human Monoclonal HRAS Primary Antibody für EIA, WB - ABIN238418 : Prior, Harding, Yan, Sluimer, Parton, Hancock: GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. in Nature cell biology 2001 (PubMed)
    Zeige alle 5 Referenzen für 238418

  3. Human Polyclonal HRAS Primary Antibody für IF, WB - ABIN655622 : van Engen-van Grunsven, van Dijk, Ruiter, Klaasen, Mooi, Blokx: HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. in The American journal of surgical pathology 2010 (PubMed)
    Zeige alle 4 Referenzen für 655622

  4. Human Polyclonal HRAS Primary Antibody für EIA, WB - ABIN360066 : Coats, Booden, Buss: Transient palmitoylation supports H-Ras membrane binding but only partial biological activity. in Biochemistry 1999 (PubMed)
    Zeige alle 3 Referenzen für 360066

  5. Human Polyclonal HRAS Primary Antibody für IF, IHC (p) - ABIN392183 : Maemoto, Yumoto, Ibata, Torizuka, Ozawa, Tatsumi, Hashido, Morikawa, Maeda, Imai: Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines. in Odontology / the Society of the Nippon Dental University 2012 (PubMed)
    Zeige alle 2 Referenzen für 392183

Weitere Antikörper gegen HRAS Interaktionspartner

Cow (Bovine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Interaktionspartner

  1. Data demonstrate that H-Ras activation is important in the activation of the specific signaling events leading to the accelerated retinal capillary cell apoptosis in hyperglycemic conditions.

  2. Activation of H-Ras and its downstream signaling pathway in the retina and its vasculature could be under the control of superoxide, and H-Ras activation in diabetes can be prevented by inhibiting superoxide accumulation.

  3. Thrombospondin 1 (zeige THBS1 Antikörper), fibronectin (zeige FN1 Antikörper), and vitronectin (zeige VTN Antikörper) are differentially dependent upon RAS, ERK1/2 (zeige MAPK1/3 Antikörper), and p38 (zeige MAPK14 Antikörper) for induction of vascular smooth muscle cell chemotaxis.

Zebrafish V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Interaktionspartner

  1. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish

Human V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Interaktionspartner

  1. Knockdown of forkhead Box M1 (FoxM1 (zeige FOXM1 Antikörper)) reduced Prx (zeige PRDX6 Antikörper) II levels in H-ras(G12V)-hepatocellular carcinoma (HCC (zeige FAM126A Antikörper)) cells, indicating FoxM1 (zeige FOXM1 Antikörper) as a direct transcription factor of Prx (zeige PRDX6 Antikörper) II in HCC (zeige FAM126A Antikörper).

  2. we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 (zeige CIB1 Antikörper) expression. We previously described the Ca(2 (zeige CA2 Antikörper)+)-myristoyl switch function of CIB1 (zeige CIB1 Antikörper), and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1 (zeige SPHK1 Antikörper)), a location where SK1 (zeige KCNN1 Antikörper) is known to elicit oncogenic signalling.

  3. Data suggest that isoform-specific sequences in the allosteric lobes of HRAS, KRAS, and NRAS (zeige NRAS Antikörper) have an impact on biocatalysis (kinetics of GTP (zeige AK3 Antikörper) hydrolysis) and interaction with c-Raf (zeige RAF1 Antikörper) kinase, which must be due to allosteric effects on dynamics and conformational states, given the identical active sites of these isoenzymes.

  4. Data suggest HRas activates both p110alpha and p110delta isoforms; membrane-resident HRas, not soluble HRas, increases membrane recruitment of both p110alpha and p110delta. (HRas = v-Ha-ras Harvey rat sarcoma viral oncogene homolog; p110alpha = class IA phosphoinositide 3-kinases, subunit p110alpha; p110delta = class IA phosphoinositide 3-kinases, subunit p110delta)

  5. Our data suggest that testing for any RAS mutation is unlikely to change the clinical management of thyroid nodules that have indeterminate cytology

  6. Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS and RRAS2 to the RAS binding (RB) domain of binding proteins.

  7. Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types.

  8. 6 of 7 (86%) malignant ectomesenchymomas had HRAS mutations

  9. RAS-positive thyroid cancer most often demonstrates indolent sonographic features and more commonly associates with lower risk, "indeterminate" cytology.

  10. Studies indicate that the control of spatiotemporal RAS protein signalling show that activation kinetics and subcellular compartmentalisation are tightly coupled to the generation of specific biological outcomes.

Mouse (Murine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Interaktionspartner

  1. KrasG12D-driven proliferation of pancreatic ductal epithelial cells (PDECs) depends on an EGFR (zeige EGFR Antikörper) signaling loop engaging the oncogenic transcription factor c-MYC (zeige MYC Antikörper).

  2. median survival of KPIC mice was longer than that of LSL-KrasG12D; Ink4flox/flox; Ptf1/p48 (zeige PTF1A Antikörper)-Cre mice (KIC) (89 vs 62 days) and shorter than that of KRAS (KrasG12D), TP53 (zeige TP53 Antikörper) (Trp53R172H/+) and Ptf1/p48 (zeige PTF1A Antikörper)-Cre (KPC) mice

  3. Loss of N-cadherin in the context of oncogenic K-ras leads to increased pancreatic intraepithelial neoplasia (PanIN) incidence and progression.

  4. p21 (zeige D4S234E Antikörper)-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 (zeige D4S234E Antikörper) and ras(Ha)/ROCK2 (zeige ROCK2 Antikörper)/NF-kappaB (zeige NFKB1 Antikörper) signalling in skin carcinogenesis.these data show that ROCK2 (zeige ROCK2 Antikörper) activation induces malignancy in ras(Ha)-initiated/promoted papillomas in the context of p53 (zeige TP53 Antikörper) loss and novel NF-kappaB (zeige NFKB1 Antikörper) expression

  5. activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis

  6. the Kras(mut (zeige MUT Antikörper)) allele was heterogenous in primary tumors yet homogenous in metastases, a pattern consistent with activated Kras(mut (zeige MUT Antikörper)) signaling being a driver of progression to metastasis.

  7. Using an extensive collection of novel murine cell lines we have identified distinct roles for Kras and Pten (zeige PTEN Antikörper) on MUC1 (zeige MUC1 Antikörper) and EMT (zeige ITK Antikörper) in vivo and in vitro. The data has implications for future design of combination therapies targeting Kras mutations, Pten (zeige PTEN Antikörper) deletions and MUC1 (zeige MUC1 Antikörper) vaccines.

  8. a potent tumor-suppressive function for Lfng (zeige LFNG Antikörper)

  9. pancreatic ductal cells, whereas exhibiting relative resistance to oncogenic Kras alone, can serve as an effective cell of origin for pancreatic ductal adenocarcinoma in the setting of gain-of-function mutations in p53 (zeige TP53 Antikörper)

  10. In vivo treatment of the KRAS(G12D)-induced Langerhans cell histiocytosis -like mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, implicating statins as potential therapeutics against a subset of pulmonary Langerhans cell histiocytosis.

HRAS Antigen-Profil

Beschreibung des Gens

This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.

Alternative names and synonyms associated with HRAS

  • Harvey rat sarcoma viral oncogene homolog (hras) Antikörper
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) Antikörper
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog a (hrasa) Antikörper
  • neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) Antikörper
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) Antikörper
  • Harvey rat sarcoma viral oncogene homolog (HRAS) Antikörper
  • Harvey rat sarcoma virus oncogene (Hras) Antikörper
  • Harvey rat sarcoma virus oncogene 1 (Hras1) Antikörper
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (Hras) Antikörper
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) Antikörper
  • AI929937 Antikörper
  • C-BAS/HAS Antikörper
  • c-H-ras Antikörper
  • c-Ha-ras Antikörper
  • C-HA-RAS1 Antikörper
  • c-rasHa Antikörper
  • CTLO Antikörper
  • H-ras Antikörper
  • H-RASIDX Antikörper
  • Ha-ras Antikörper
  • HAMSV Antikörper
  • Harvey-ras Antikörper
  • hras Antikörper
  • Hras-1 Antikörper
  • HRAS1 Antikörper
  • K-ras Antikörper
  • Ki-ras Antikörper
  • Kras-2 Antikörper
  • Kras2 Antikörper
  • N-RAS Antikörper
  • p21B Antikörper
  • ras Antikörper
  • RASH1 Antikörper
  • zgc:110250 Antikörper

Bezeichner auf Proteinebene für HRAS

v-Ha-ras Harvey rat sarcoma viral oncogene homolog , small G-protein H-Ras , Harvey ras 1 , p19 H-RasIDX protein , GTPase HRas (Transforming protein p21) (H-Ras-1) (c-H-ras) , xRAS1 , GTPase HRas , Transforming protein p21 , neuroblastoma ras oncogene , GTP- and GDP-binding peptide B , H-Ras-1 , Ha-Ras1 proto-oncoprotein , Ras family small GTP binding protein H-Ras , c-has/bas p21 protein , c-ras-Ki-2 activated oncogene , p21ras , transformation gene: oncogene HAMSV , transforming protein p21 , Harvey ras1 protein , Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog , H-ras 1 protein , c-Ha-ras p21 protein , c-Ha-ras transgene , transforming protein P21 , GTPase NRas , transforming protein N-Ras , c-H-ras , v-Ha-ras Harvey rat sarcoma viral oncogene-like protein , ras p21 , GTPase KRas , K-Ras 2 , Kirsten rat sarcoma oncogene 2, expressed , c-K-ras , c-Ki-ras , p21 protein

399406 Xenopus laevis
466302 Pan troglodytes
513012 Bos taurus
549757 Xenopus (Silurana) tropicalis
550286 Danio rerio
698830 Macaca mulatta
733587 Sus scrofa
100222058 Taeniopygia guttata
100227892 Taeniopygia guttata
3265 Homo sapiens
293621 Rattus norvegicus
15461 Mus musculus
100739349 Sus scrofa
100735038 Cavia porcellus
396229 Gallus gallus
403735 Canis lupus familiaris
100298939 Bos taurus
101104357 Ovis aries
16653 Mus musculus
Ausgewählte Anbieter für anti-HRAS (HRAS) Antikörper
Haben Sie etwas anderes gesucht?